SciClone Pharmaceuticals Inc

SciClone Pharmaceuticals — Investor Presentation (January 2010)

22 slides from SciClone Pharmaceuticals's investor presentation, Jan 11, 2010

  1. Slide 1: Global Strategies for Life-Enhancing Drugs

    Exhibit 99.2 Global Strategies for Life-Enhancing Drugs Corporate Presentation January 2010

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements regarding development objectives and timing expectations. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "exp

  3. Slide 3: Global Specialty Pharma Company: Profit-driven and Growing

    Global Specialty Pharma Company Profit-driven and Growing • Significant profitability and cash flow positive • 2009 financial results and outlook: • Approximately $72.4 MM revenue (unaudited); 34% increase • Approximately $31.8 MM cash & investments (unaudited) at 12/31/09 • $0.18 - $0.22 current EP

  4. Slide 4: Committed to Sustained Profitability and Growing EPS

    Committed to Sustained Profitability and Growing EPS 2009 Financial Results and Outlook • Revenue of $72.4 MM A** • EPS: $0.18 to $0.22 E** • Cash and investments of $31.8 MM A** Revenue (MM) $100.0 $80.0 $60.0 $40.0 $20.0 $.0 2006 2007 2008 2009 A** 2010 E** EPS: ($.16)* ($.22) ($.18) $0.18 - $0.22

  5. Slide 5: Specialty Pharma Focus in China: Significant Growth Opportunity for SciClone

    Specialty Pharma Focus in China: Significant Growth Opportunity for SciClone

  6. Slide 6: Growth Opportunity: SciClone in China

    Growth Opportunity: SciClone in China • Chinese Pharmaceutical Market • China expected to rank among the top five global pharmaceutical markets by 2012 and 2nd in market size growth • Growth of approximately 23%* over the next three years • Our Position/Opportunity • Longstanding presence in China s

  7. Slide 7: China Healthcare Reform Plan Update

    China Healthcare Reform Plan Update • Thymosin alpha 1 (ZADAXIN generic name) included in Class B of China’s National Drug Reimbursement List (“NDRL”) in November 2009 • NDRL consists of >2,100 drugs • Important component of the healthcare reform plan in China • Government aiming for universal healt

  8. Slide 8: Product Portfolio

    Product Portfolio Product Development Phase 1 Phase 2 Phase 3 Marketed ® ZADAXIN HBV/HCV & Other Indications China, Russia & >30 other countries H1N1 Vaccine Enhancement Marketing approval Italy & 12 countries; global targeted 1H 2010 Stage IV Melanoma U.S./Europe DC Bead™ Marketing approval Liver c

  9. Slide 9: ZADAXIN Development Opportunity: A High Value Drug for H1N1

    ZADAXIN Development Opportunity: A High Value Drug for H1N1

  10. Slide 10: ZADAXIN Enhancement of Vaccine for H1N1 Virus

    ZADAXIN Enhancement of Vaccine for H1N1 Virus Description • ZADAXIN, a synthetic preparation of naturally and MOA occurring peptide with immunostimulatory activity which promotes antibody production •Potential to develop ZADAXIN as an enhancer of novel H1N1 flu vaccines globally • Targeting immune c

  11. Slide 11: ZADAXIN Enhancement of Vaccine for H1N1 Virus

    ZADAXIN Enhancement of Vaccine for H1N1 Virus Development •Targeting a new dosage regimen effective with one or Strategy two injections • Preclinical studies completed in late 2009 • Clinical studies underway in Italy • Using H1N1 vaccine - Novartis Focetria™ Future • Past experience showed there ma

  12. Slide 12: Phase 2 Drug Candidate in Two Indications: SCV-07

    Phase 2 Drug Candidate in Two Indications: SCV-07

  13. Slide 13: SCV-07: Phase 2 Oral Mucositis (OM) Opportunity

    SCV-07: Phase 2 Oral Mucositis (OM) Opportunity Description • Novel dipeptide inhibits STAT-3 signaling leading to and MOA dendritic cell maturation and increased Th1 cytokine production • Restores balance in Th1/Th2 helper T cell ratio (ratio shifted to Th2 by radiation) • Subcutaneously as well as

  14. Slide 14: SCV-07: Phase 2 Oral Mucositis Opportunity

    SCV-07: Phase 2 Oral Mucositis Opportunity Development • Double-blind, placebo controlled, phase 2 trial to delay Strategy the onset of severe OM in head and neck cancer patients and decrease its severity • Enrollment completed in 2H 2009 Future • Topline results to be reported in 1H 2010 Developmen

  15. Slide 15: SCV-07: Phase 2 HCV Opportunity

    SCV-07: Phase 2 HCV Opportunity Description • Novel dipeptide inhibits STAT-3 signaling leading to and MOA dendritic cell maturation and increased Th1 cytokine production • Increases Th1-type immune responses (Th1 responses needed for viral clearance of infected cells) • Subcutaneously as well as or

  16. Slide 16: SCV-07: Phase 2 HCV Opportunity

    SCV-07: Phase 2 HCV Opportunity Development • Initial 7 day monotherapy study reported at EASL Strategy showed SCV-07 is safe • Viral load reduction and increased biomarker (neopterin) of macrophage activation seen in some patients • Phase 2 trial of SCV-07 lead-in monotherapy followed by combinatio

  17. Slide 17: DC Bead: Targeting Liver Cancer in China

    DC Bead: Targeting Liver Cancer in China Description • Embolic agent, delivers chemotherapy drugs • Microscopic beads with dual anti-tumor effects • Deliver doxorubicin, potentially other chemotherapy agents directly to tumor Commercial • Exclusive Chinese marketing rights Opportunity • Market-speci

  18. Slide 18: Ondansetron RapidFilm

    Ondansetron RapidFilm™ Description • Serotonin 5-HT3 receptor antagonist commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery • Innovative oral thin film formulation of ondansetron Commercial • Commercialization rights in China and Vietnam Opportun

  19. Slide 19: Corporate Progress

    SE: Corporate Progress

  20. Slide 20: Milestones

    Milestones Milestone Timeline 2009 revenue guidance $70-$72 MM; $72.4 MM Actual Completed Complete preclinical studies evaluating the treatment regimen for Completed ZADAXIN as an enhancer of H1N1 pandemic flu vaccine Initiate clinical studies evaluating the treatment regimen for ZADAXIN as Complete

  21. Slide 21: Global Specialty Pharma Company: Profit-driven and Growing

    Global Specialty Pharma Company Profit-driven and Growing • Significant profitability and cash flow positive • 2009 financial results and outlook: • Approximately $72.4 MM revenue (unaudited); 34% increase • Approximately $31.8 MM cash & investments (unaudited) at 12/31/09 • $0.18 - $0.22 current EP

  22. Slide 22: Global Strategies for Life-Enhancing Drugs

    Global Strategies for Life-Enhancing Drugs Corporate Presentation January 2010

SciClone Pharmaceuticals — Investor Presentation (January 2010) on 6ix